Emmes, Miimansa AI Partner on Generative AI in Clinical Research

Emmes Group, a specialty tech-enabled global CRO, entered a multi-year strategic partnership with Miimansa AI aimed at advancing clinical research at Emmes, leveraging Miimansa’s Clinical Entity Modeling tools based on advanced large language modeling (LLM) techniques and generative AI.

Emmes Group is working to advance its technology platform, Veridix AI, and Miimansa’s Clinical Entity Modeling technology will be leveraged to help accelerate the development of automated text processing solutions tailored for clinical research.

The partnership will focus on creating capabilities for quickly and accurately processing vast amounts of clinical data and enabling text to text transformations such as protocol authoring and medical writing, reducing the time and cost associated with manual data handling and analysis.

“We are excited to partner with Miimansa AI to bring cutting-edge AI technology to the forefront of clinical research,” said Sastry Chilukuri, CEO of Emmes Group. “The clinical entity modeling tools acquired through our partnership will accelerate development and adoption of Emmes Groups’ Gen AI platform, named Concord, to drive faster, better and more efficient clinical trials.”

Dr. Vibhu Agarwal, founder and CEO of Miimansa AI, added, “Teaming up with Emmes Group is a significant milestone for us. Their expertise and comprehensive clinical trial data offer a unique opportunity to apply our advanced AI techniques in real-world settings. Together, we aim to transform the landscape of clinical research, making it faster, more affordable, and ultimately more successful in delivering safe and effective treatments.”